Novavax Announces Ebola Vaccine Development Program at the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Novavax Announces Ebola Vaccine Development Program at the 8th Vaccine and ISV Conference in Philadelphia
  • First Ebola Vaccine Candidate based on the 2014 Guinea Ebola Strain Genetic Sequence
  • Robust immune responses demonstrated in preclinical studies; exceptional responses when used with Novavax' Matrix-M™ adjuvant
  • Non-human primate study initiated
  • GMP manufacture initiated; Scaled-up manufacturing to begin 1 st quarter 2015
  • Phase 1 clinical trial anticipated to start in December 2014

GAITHERSBURG, Md., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX ) today announced that Gale Smith, Ph.D., Vice President of Vaccine Development at Novavax, presented at the 8 th Vaccine and ISV Conference in Philadelphia on Sunday, October 26. Dr. Smith's presentation was titled: 2014 Guinea Ebola Virus Recombinant Glycoprotein (GP) Nanoparticle Vaccine was Highly Immunogenic and Cross-Neutralized 1976 Virus GP Pseudovirus.

Dr. Smith reported on Novavax' Ebola GP recombinant nanoparticle vaccine candidate (EBOV GP Vaccine), which is based on the 2014 Guinea Ebola strain that is responsible for the current Ebola disease epidemic in West Africa. In preclinical models, the EBOV GP Vaccine induced antibody titers against the homologous 2014 Guinea Ebola GP in the range of 10 3 to 10 4 (ELISA EC 90). Aluminum phosphate as an adjuvant resulted in a modest adjuvant effect; however, the Company's proprietary adjuvant Matrix-M™ enhanced anti-Ebola GP responses by 10 to 100 fold, inducing Ebola GP antibody titers of 10 5 to 10 6 (ELISA EC90). Importantly, EBOV GP vaccine plus Matrix-M induced serum cross-neutralization to the older Ebola 1976 (Mayinga) GP-VSV pseudotype. The EBOV GP Vaccine, adjuvanted with Novavax' Matrix-M adjuvant, induced anti-GP ELISA and neutralizing antibody levels well within ranges reported to protect against Ebola viruses in rodent and non-human primate models.

"We are developing our recombinant Ebola GP vaccine using the same platform we used to develop vaccine candidates against several pathogens including respiratory syncytial virus (RSV), seasonal and pandemic influenza, and Middle Eastern Respiratory Syndrome (MERS)," said Stanley C. Erck, President and CEO. "Our proprietary platform allows us to quickly develop, and manufacture an Ebola vaccine candidate at large scale, which we believe can provide a necessary tool to fight this global health crisis."

Novavax has recently initiated a non-human primate study and expects to initiate a Phase 1 clinical trial in December 2014 to evaluate the safety and immunogenicity of the EBOV GP Vaccine in ascending doses, with and without the Matrix-M adjuvant, in approximately 150 subjects. Plans to demonstrate the safety and efficacy in a large-scale global clinical trial will be developed based on data from the Phase 1 trial and in collaboration with global regulatory authorities and world health agencies.

"We used the recently published Guinea 2014 Ebola strain genetic sequence 1 to create a highly purified, correctly folded, Ebola GP Vaccine in only a few weeks," said Gregory Glenn, M.D., SVP, Research and Development at Novavax. "The data presented today provides scientific validation that our technology platform can respond to emerging viral threats in an extremely efficient and effective manner. We look forward to the results of our non-human primate study and the initiation of a Phase 1 clinical trial in the near future."

The Novavax EBOV GP Vaccine may also address other key requirements for a successful vaccine against this viral threat: (1) like Novavax' other recombinant vaccines, it appears to not require frozen storage allowing for easier transport and more efficient global distribution; (2) manufacturing could be rapidly scaled to millions of doses a month, based on the Company's experience in scale-up and manufacturing with its other nanoparticle vaccine candidates, and; (3) the preclinical data suggest that the Matrix-M adjuvant enhances immunogenicity with lower doses of antigen, which would further leverage the company's ability to manufacture and supply significant doses.

About Novavax

Novavax, Inc. (Nasdaq: NVAX ) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Novavax has vaccine candidates in late stage clinical trials for respiratory syncytial virus, and for seasonal and pandemic influenza. Additional information about Novavax is available on the company's website, novavax.com.

Corporate B-roll footage available to media upon request.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading " Risk Factors " in the Novavax Annual Report on Form 10-K for the year ended December 31, 2013, and filed with the Securities and Exchange Commission (SEC). Investors are cautioned not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read company filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and the company undertakes no obligation to update or revise any of the statements. The company ' s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

1 Gire, S., et al., Science , 345, 6202 (1369-72) 2014

Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 David Schull or Andrea Flynn, Ph.D. Russo Partners, LLC 212-845-4271

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 0

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 222

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 301

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 139

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 11

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 49

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading

Top 5 Most Recently Viewed Articles

Breaking News: Sportswear Highlights and Streaming Drama Unfolds

Updated Category News Views 235

New On The Block Puma SE, a Germany-based sportswear company, is drawing interest from several buyers in Asia. Notable bids are coming from China's Anta Sports and Li Ning Co., alongside Japan's Asics Corp. As the market responds to this potential sale, the implications for both Puma and the interested firms may shift the dynamics in the sportswear industry. The Netflix...

Continue Reading
Bridging the AI Adoption Gap for Modern Enterprises

Updated Category News Views 103

Navigating the Challenges of AI Adoption in Enterprises In today's fast-paced business landscape, the integration of artificial intelligence (AI) has become more crucial than ever. A recent survey conducted by Unily highlights a pressing concern: many enterprises are struggling to keep pace with AI adoption. The findings reveal that nearly 40% of employees feel their...

Continue Reading
Cryptocurrency Market Trends: Key Insights on Bitcoin and More

Updated Category News Views 393

Cryptocurrency Market Holds Steady Amid Economic Shifts Recently, the cryptocurrency market has shown remarkable stability despite fluctuating stock indices. As economic factors shift, particularly with recent job data revisions, market expectations for interest rate changes have intensified. Bitcoin Sees Minor Decline Bitcoin momentarily surged past $113,000 before...

Continue Reading
Exploring Earnings Insights for Stantec's Upcoming Report

Updated Category News Views 77

Stantec's Upcoming Earnings Report Overview Stantec (NYSE: STN) is preparing to release its latest quarterly earnings report soon. Investors are gearing up in anticipation of what this report might reveal about the company's financial health and future outlook. Analysts' Earnings Predictions Experts are estimating that Stantec will announce an earnings per share (EPS) of...

Continue Reading
Yarbo Unleashes the M Series: Transforming Yard Care

Updated Category News Views 45

Dust off your lawn chairs, folks, because Yarbo is strutting into IFA 2026 with its M Series, a real game-changer in yard robotics. These aren't just fancy grass clippers; they're smart machines turning yard care on its head. Ever wrestle with a rake or push a lawn mower when you'd rather be soaking in some sun? Well, you're in luck. From Dream to Dirt: M Series Arrives...

Continue Reading